FGF9 and prostate carcinoma: The findings in this study revealed that enhanced expression of Cx3cr1 after Klf5KR knockin in Pten-deficient prostate cancer is an endogenous molecular mechanism by which FGFR1 signaling is activated by its paracrine ligand FGF9 (Figure 8).